Tests two immune-lowering treatments for IgA nephropathy with advanced kidney disease
Compares low-dose prednisolone alone with prednisolone plus cyclophosphamide in adults with IgA nephropathy.
Plain-language title generated from the registry record
Registry title: Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Key facts
- Where
- Xi'an, ChinaSee the site
- Phase
- Phase 3
Where in China
- AFMMUXi'an, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Air Force Military Medical University, China
- Trial code
- NCT05510323
- Record updated
- 6 May 2024
- Original description
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.Read full original descriptionShow less
Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney Disease
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.
Inclusion: Biopsy-proven IgA nephropathy; Proteinuria ≥1.0g/day while receiving maximum tolerated dose of RAS blockade; Estimated glomerular filtration rate 15-60 ml/min/1.73/m2.
Exclusion: Indication or contraindication for immunosuppressive therapy with corticosteroids; Use of corticosteroids and other immunosuppressive drugs within the last 1 year; Under 18 years old; Current unstable kidney function for other reasons; Patients with secondary IgAN; Patients who are unlikely to comply with the study protocol in the view of the treating physician.